natgillin/translations-raw huggingface dataset:
I studiet TAX 316 forekom lymfødem i løbet af behandlingsperioden og fortsatte ind i opfølgningsperioden efter afsluttet kemoterapi og blev rapporteret hos 11 af 744 TAC patienter (1,5 %) og hos 1 af 736 FAC patienter (0,1 %). 
In study TAX316 lymphoedema that started during the treatment period and persisted into the followup period after the end of chemotherapy was reported in 11 of 744 TAC patients (1.5%) and 1 of 736 FAC patients (0.1%).
Trombocytopeni; (G3/4: 0,6 %); 
Thrombocytopenia (G3/4: 0.6%);
PSA**- response rate (%) 95 %CI p-værdi* 
Number of patients PSA** response rate (%) 95% CI p-value*
Ikke almindelige (kan forekomme hos op til 1 ud af 100 patienter): 
Uncommon (may affect up to 1 in 100 people):
Paræsthesi (G3/4: < 1 %) 
Epistaxis (G3/4: < 1%)
Bedste respons i alt til kemoterapi (%) (95 %CI) ***p-værdi 
Best overall response to chemotherapy (%) (95% CI) ***p-value
Medmindre det er kontraindiceret, kan der til brystkræft og ikke-småcellet lungekræft gives et peroralt kortikosteroid som præmedicinering, eksempelvis dexamethasone 16 mg per dag i 3 dage (f.eks. 8 mg 2 gange daglig). 
For breast, non-small cell lung, gastric, and head and neck cancers, premedication consisting of an oral corticosteroid, such as dexamethasone 16 mg per day (e.g. 8 mg BID) for 3 days starting 1 day prior to docetaxel administration, unless contraindicated, can be used (see section 4.4).
Anoreksi (G3/4: 0.6 %) 
Anorexia (G3/4: 0.6%)
Efter 10 års opfølgning i TAX 316-studiet blev akut leukæmi rapporteret hos 3 ud af 744 TACpatienter (0,4 %) og hos 1 ud af 736 FAC-patienter (0,1%). 
After 10 years of follow up in study TAX316, acute leukaemia was reported in 3 of 744 TAC patients (0.4%) and in 1 of 736 FAC patients (0.1%).
Ved den mediane opfølgningsperiode på 77 måneder var den samlet overlevelse (SO) også længere i TAC- armen, hvor TAC-behandlede patienter havde 24 % lavere risiko for død sammenlignet med FAC- behandlede patienter (hazard ratio = 0,76; 95 % CI (0,46-1,26; p=0,29). 
At the median follow-up time of 77 months overall survival (OS) was also longer in the TAC arm with TAC-treated patients having a 24% reduction in the risk of death compared to FAC (hazard ratio = 0.76, 95% CI (0.46-1.26, p = 0.29).
DOCETAXEL KABI er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk ikke-småcellet lungekræft efter behandlingssvigt af kemoterapi. 
DOCETAXEL KABI is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.
Iskæmisk hjertesygdom 
Cardiac failure
Myalgi (G3/4: 0,7 %); Artralgi (G3/4: 0,2 %) 
Myalgia (G3/4: 0.7%); Arthralgia (G3/4: 0.2%)
Letargi (G3/4: 19,0 %); Feber (G3/4: 2,3 %); 
Lethargy (G3/4: 19.0%); Fever (G3/4: 2.3%);
Hjerte: 
arm.
Nedsat venstre ventrikelfunktion (G3/4: 0,3 %) 
Cardiac left ventricular function decrease (G3/4: 0.3%)
Dyspnø (G3/4: 1 %); Hoste (G3/4: < 1 %); 
Dyspnoea (G3/4: 1%); Cough (G3/4: < 1%);
Beskrivelse af udvalgte bivirkninger ved behandling af brystkræft med DOCETAXEL KABI 100 mg/m2 i kombination med trastuzumab 
Description of selected adverse reactions in breast cancer for DOCETAXEL KABI 100 mg/m² in combination with trastuzumab
For de patienter med serum-bilirubin > øvre normalværdi og/eller ALAT og ASAT > 3,5 gange øvre normalværdi og basiske fosfataser > 6 gange øvre normalværdi, kan det ikke anbefales at reducere dosis. 
For those patients with serum bilirubin > ULN and/or ALT and AST > 3.5 times the ULN associated with alkaline phosphatase > 6 times the ULN, no dose-reduction can be recommended and docetaxel should not be used unless strictly indicated.
Ved den mediane opfølgningsperiode på 77 måneder var den totale overlevelse (OS) længere i TACarmen, hvor TAC-behandlede patienter havde 24 % lavere risiko for død sammenlignet med FACbehandlede patienter (hazard ratio = 0,76; 95 % CI (0,46-1,26; p=0,29). 
At the median follow-up time of 77 months, overall survival (OS) was longer in the TAC arm with TAC-treated patients having a 24% reduction in the risk of death compared to FAC (hazard ratio = 0.76, 95% CI (0.46-1.26, p = 0.29).
Tabel over bivirkninger ved behandling af prostatakræft med DOCETAXEL KABI 75 mg/m² i kombination med prednison eller prednisolon 
Tabulated list of adverse reactions in prostate cancer for DOCETAXEL KABI 75 mg/m² in combination with prednisone or prednisolone
Flebitis (G3/4: 0 %) 
Phlebitis (G3/4: 0%)
• Smagsforstyrrelser 
• alteration in sense of taste
DOCETAXEL KABI i kombination med doxorubicin er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk brystkræft, som ikke tidligere har fået kemoterapi mod denne tilstand. 
DOCETAXEL KABI in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.
Docetaxel forlængede median-tiden til progression (24,6 uger vs 15,6 uger; p < 0,01) og median- overlevelse (15,3 måneder vs 12,7 måneder; 
Without affecting the primary endpoint, overall response rate (32% vs 25%, p = 0.10), docetaxel prolonged median time to progression (24.6 weeks vs 15.6 weeks; p < 0.01) and median survival (15.3 months vs 12.7 months; p = 0.03).
INDHOLD ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER 180 mg/9 ml ANDET Cytotoksisk 
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 180 mg/9 ml OTHER Cytotoxic
Hver æske indeholder 1 hætteglas af 9 ml (180 mg docetaxel). 
Each box contains one vial of 9 ml concentrate (180 mg docetaxel).
Trombocytopeni (G4:0,5 %) 
Thrombocytopenia (G4: 0.2%)
Ved afslutningen af opfølgningsperioden blev det observeret (median opfølgningstid på 8 år), at asteni fortsatte hos 29 TAC patienter (3,9 %) og hos 16 FAC patienter (2,2 %). 
At the end of the follow-up period (actual median follow-up time of 8 years), asthenia was observed to be ongoing in 29 TAC patients (3.9%) and 16 FAC patients (2.2%).
Infektioner (G3/4: 3,3 %) 
Infection (G3/4: 3.3%)
G3/4 Forhøjet bilirubin i blodet (9 %) 
G3/4 Blood bilirubin increased (< 2%)
Forhøjet lakrimation (G3/4: 0 %) 
Lacrimation increased (G3/4: 0%)
Docetaxel blev elimineret både i urin og fæces efter cytocrom P-450 medieret oxidativ metabolisering af tert-butyl estergruppen. 
Docetaxel was eliminated in both the urine and faeces following cytochrome P450-mediated oxidative metabolism of the tert-butyl ester group, within seven days, the urinary and faecal excretion accounted for about 6% and 75% of the administered radioactivity, respectively.
Diarré (G3/4: 3,4 %); Obstipation (G3/4:0,5 
Diarrhoea (G3/4: 3.4%); Constipation (G3/4: 0.5%)
Perifer sensorisk neuropati (G3: 0,4 %) 
Peripheral sensory neuropathy (G3: 0.4%)
Hver æske indeholder 1 hætteglas af 6 ml (120 mg docetaxel). 
Each box contains one vial of 6 ml concentrate (120 mg docetaxel).
Hver æske indeholder 1 hætteglas af 8 ml (160 mg docetaxel). 
Each box contains one vial of 8 ml concentrate (160 mg docetaxel).
DOCETAXEL KABI indeholder: 
You must not be given DOCETAXEL KABI:
I studiet TAX316 forekom perifer sensorisk neuropati i løbet af behandlingsperioden og fortsatte ind i opfølgningsperioden hos 84 patienter (11,3 %) i TAC-armen og hos 15 patienter (2 %) i FAC-armen. 
In study TAX316 peripheral sensory neuropathy started during the treatment period and persisted into the follow-up period in 84 patients (11.3%) in TAC arm and 15 patients (2 %) in FAC arm. At the end of the follow-up period (median follow-up time of 8 years), peripheral sensory neuropathy was observed to be ongoing in 10 patients (1.3%) in TAC arm, and in 2 patients (0.3%) in FAC arm.
Vedrørende dosisjusteringer for trastuzuma, se produktresuméet for trastuzumab. 
For trastuzumab dose modifications, see trastuzumab summary of product characteristics.
Beskrivelse af udvalgte bivirkninger ved behandling af brystkræft med DOCETAXEL KABI 100 mg/m2 enkeltstof 
Description of selected adverse reactions in breast cancer for DOCETAXEL KABI 100 mg/m² single agent
I de følgende tilfælde bør docetaxel-dosis reduceres til 65 mg/ m2 i de følgende behandlingsrunder: 1) hos patienter med en initialdosis på 75 mg/m2 docetaxel i kombination med cisplatin, med en minimum blodpladeværdi under den tidligere behandlingsrunde på < 25000 celler/mm3 2) hos patienter, der får febril neutropeni, 3) hos patienter, med alvorlig, ikke-hæmatologisk toksicitet. 
For patients who are dosed initially at docetaxel 75 mg/m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is < 25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/m2.
Perifer motorisk neuropati (G3/4: 0 %) 
Peripheral motor neuropathy (G3/4: 0%)
Bortskaffelse: 
Disposal
INDHOLD ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER 160 mg/8 ml ANDET Cytotoksisk 
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 160 mg/8 ml OTHER Cytotoxic
Et hætteglas af 9 ml koncentrat indeholder 180 mg docetaxel. 
One vial of 9 ml of concentrate contains 180 mg of docetaxel.
Patienter bør modtage kemo-strålingsterapi efter kemoterapi 
Following chemotherapy, patients should receive chemoradiotherapy.
Brug ikke DOCETAXEL KABI 
You must not be given DOCETAXEL KABI
I studiet GEICAM9805 blev det observeret, at amenorré, som forekom i løbet af behandlingsperiden og fortsatte ind i opfølgningsperioden fortsat blev observeret hos 18 patienter (3,4 %) i TAC-armen og hos 5 patienter (1,0 %) i FAC-armen. 
In GEICAM 9805 study amenorrhoea that started during the treatment period and persisted into the follow-up period was observed to be ongoing in 18 patients (3.4 %) in TAC arm and 5 patients (1.0 %) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), amenorrhoea was observed to be ongoing in 7 patients (1.3%) in TAC arm, and in 4 patients (0.8%) in FAC arm.
- Aktivt stof: docetaxel vandfri. 
What DOCETAXEL KABI contains - The active substance is docetaxel anhydrous.
DOCETAXEL KABI i kombination med trastuzumab er indiceret til behandling af patienter med metastatisk brystkræft, som har HER2-positive tumorer, og som ikke tidligere har fået kemoterapi mod metastatisk sygdom. 
DOCETAXEL KABI in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.
Et hætteglas af 8 ml koncentrat indeholder 160 mg docetaxel. 
One vial of 8 ml of concentrate contains 160 mg of docetaxel.
• Blodpropper 
• blood clots.
Kvalme (G3/4: 3,3 %); 
Nausea (G3/4: 3.3%);
Gastrointestinal Hæmoragi (alvorlig: 
Gastrointestinal haemorrhage (severe: 0.3%)
Dysgeusi (G3/4: < 1 %); Paræsthesi (G3/4: < 1 %) 
Dysgeusia (G3/4: < 1%); Paraesthesia (G3/4: < 1%)
Hver æske indeholder 1 hætteglas af 4 ml (80 mg docetaxel). 
Each box contains one vial of 4 ml concentrate (80 mg docetaxel).
Forhøjet lakrimation (G3/4:0,6 %) 
Lacrimation increased (G3/4: 0.6%)
UTILGÆNGELIGT FOR BØRN 
NA-not applicable
Median overlevelse i alt (måneder) (95% CI) 
Median overall survival (months) (95% CI)
10 ml klar, farveløs Type-I hætteglas, lukket med flurotec gummipropper og en orange flip-off aluminium kapsel, indeholdende 9 ml koncentrat. 
10 ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a orange flip-off aluminium over seal containing 9 ml of concentrate.
• Muskelømhed og smerter, rygsmerter eller knoglesmerter 
• muscle aches and pains; back pain or bone pain
Der er rapporter om knoglemarvsdepression og andre hæmatologiske bivirkninger. 
Bone marrow suppression and other haematologic adverse reactions have been reported.
FREMSTILLINGSVEJLEDNING TIL BRUG FOR DOCETAXEL KABI 180 mg/9 ml, KONCENTRAT TIL INFUSIONSVÆSKE, OPLØSNING 
PREPARATION GUIDE FOR USE WITH DOCETAXEL KABI 180 mg/9 ml CONCENTRATE FOR SOLUTION FOR INFUSION
Tabel over bivirkninger ved behandling af brystkræft med DOCETAXEL KABI 75 mg/m² i kombination med capecitabin: 
Tabulated list of adverse reactions in breast cancer for DOCETAXEL KABI 75 mg/m² in combination with capecitabine
I studiet TAX 316 blev alopeci, der fortsatte ind i opfølgningsperioden efter endt kemoterapi, rapporteret hos 687 af 744 TAC-patienter (92,3%) og 645 af 736 FAC-patienter (87,6%). 
In study TAX316 alopecia persisting into the follow-up period after the end of chemotherapy was reported in 687 of 744 TAC patients (92.3%) and 645 of 736 FAC patients(87.6%).
Perifer motorisk neuropati (G3/4: 0,4 %) 
Peripheral motor neuropathy (G3/4: 0.4%)
Myalgi (G3/4: 0,6 %) 
Myalgia (G3/4: 0.6%)
INDHOLD ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER 120 mg/6 ml ANDET Cytotoksisk 
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 120 mg/6 ml OTHER Cytotoxic
DOCETAXEL KABI i kombination med platinmidler hos patienter der ikke tidligere er behandlet med kemoterapi 
DOCETAXEL KABI in combination with platinum agents in chemotherapy-naïve patients
Toksikologiske studier på gnavere har vist uønskede påvirkninger af testisfunktionen. 
Undesirable effects on the testis observed in rodent toxicity studies suggest that docetaxel may impair male fertility.
Kvalme (G3/4: 5 %); 
Nausea (G3/4: 5%);
LÆGEMIDLETS NAVN DOCETAXEL KABI 180 mg/9 ml koncentrat til infusionsvæske, opløsning. 
NAME OF THE MEDICINAL PRODUCT DOCETAXEL KABI 180 mg/9 ml concentrate for solution for infusion
• Ved behandling af tidlig brystkræft med eller uden spredning til lymfeknuder kan DOCETAXEL KABI anvendes i kombination med doxorubicin eller cyclophosphamid. 
- For the treatment of early breast cancer with or without lymph node involvement, DOCETAXEL
G3/4 Forhøjet bilirubin i blodet (< 5 %);G3/4 forhøjet alkalisk fosfatase i blodet 
G3/4 Blood alkaline phosphatase increased (< 4%);G3/4 AST increased (< 3%);
Et hætteglas af 6 ml koncentrat indeholder 120 mg docetaxel. 
One vial of 6 ml of concentrate contains 120 mg of docetaxel.
5,7 %; inklusive sepsis og pneumoni, letal hos 
Infections (G3/4: 5.7%; including sepsis and pneumonia, fatal in 1.7%)
DOCETAXEL KABI monoterapi er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk brystkræft efter behandlingssvigt af kemoterapi. 
DOCETAXEL KABI monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.
Hver æske indeholder 1 hætteglas af 1 ml (20 mg docetaxel). 
Each box contains one vial of 1 ml concentrate (20 mg docetaxel).
Lægemidlet indeholder 50 vol % ethanol vandfri (alkohol), dvs. op til 2,37 g (3 ml) ethanol vandfri per hætteglas svarende til 60 ml øl eller 24 ml vin. 
This medicinal product contains 50 vol % ethanol anhydrous (alcohol), i.e. up to 2.37 g ethanol anhydrous per vial of 6 ml equivalent to 60 ml of beer or 24 ml wine.
FREMSTILLINGSVEJLEDNING TIL BRUG FOR DOCETAXEL KABI 160 mg/8 ml, KONCENTRAT TIL INFUSIONSVÆSKE, OPLØSNING 
PREPARATION GUIDE FOR USE WITH DOCETAXEL KABI 160 mg/8 ml CONCENTRATE FOR SOLUTION FOR INFUSION
Trombocytopeni (G3/4: 
Thrombocytopenia (G3/4: 3%)
• Søvnløshed 
• insomnia
INDHOLD ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER 20 mg/1 ml ANDET Cytotoksisk 
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 20 mg/1 ml OTHER Cytotoxic
Myalgi (G3/4: 0,4 %) 
Myalgia (G3/4: 0.4%)
Et hætteglas af 1 ml koncentrat indeholder 20 mg docetaxel. 
One vial of 1 ml of concentrate contains 20 mg of docetaxel.
Det er et handelsnavn for docetaxel. 
Its common name is docetaxel.
INDHOLD ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER 80 mg/4 ml ANDET Cytotoksisk 
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 80 mg/4 ml OTHER Cytotoxic
I de følgende tilfælde bør dosis af docetaxel reduceres fra 100 mg/m2 til 75 mg/m2 og/eller fra 75 mg/m2 til 60 mg/m2: Hos patienter, som under docetaxel-behandling har haft enten febril neutropeni, neutrofile leukocytter < 500 celler/mm3 i mere end en uge, alvorlige eller kumulative reaktioner eller alvorlig perifer neuropati. 
In patients who experienced either febrile neutropenia, neutrophil count < 500 cells/mm3 for more than one week, severe or cumulative cutaneous reactions or severe peripheral neuropathy during docetaxel therapy, the dose of docetaxel should be reduced from 100 mg/m2 to 75 mg/m2 and/or from 75 to 60 mg/m².
DOCETAXEL KABI 180 mg/9 ml koncentrat til infusionsvæske, opløsning docetaxel 
DOCETAXEL KABI 180 mg/9 ml concentrate for solution for infusion docetaxel
Lægemidlet indeholder 50 vol % ethanol vandfri (alkohol), dvs. op til 395 mg ethanol vandfri per hætteglas svarende til 10 ml øl eller 4 ml vin. 
This medicinal product contains 50 vol % ethanol anhydrous (alcohol), i.e. up to 395 mg ethanol anhydrous per vial, equivalent to 10 ml of beer or 4 ml wine.
Lægemidlet indeholder 50 vol % ethanol vandfri (alkohol), dvs. op til 3,16 g (4 ml) ethanol vandfri per hætteglas svarende til 80 ml øl eller 32 ml vin. 
This medicinal product contains 50 vol % ethanol anhydrous (alcohol), i.e. up to 3.16 g ethanol anhydrous per vial, equivalent to 80 ml of beer or 32 ml wine.
LÆGEMIDLETS NAVN DOCETAXEL KABI 160 mg/8 ml koncentrat til infusionsvæske, opløsning. 
NAME OF THE MEDICINAL PRODUCT DOCETAXEL KABI 160 mg/8 ml concentrate for solution for infusion
Median overlevelse (måneder) (95 %CI) 
Median survival (months) (95% CI)
DOCETAXEL KABI 120 mg/6 ml koncentrat til infusionsvæske, opløsning docetaxel 
DOCETAXEL KABI 120 mg/6 ml concentrate for solution for infusion docetaxel
Nyre og urinveje 
Cough; Rhinorrhoea
LÆGEMIDLETS NAVN DOCETAXEL KABI 20 mg/1 ml koncentrat til infusionsvæske, opløsning. 
NAME OF THE MEDICINAL PRODUCT DOCETAXEL KABI 20 mg/1 ml concentrate for solution for infusion
Hoved-og hals-kræft 
Head and neck cancer
DOCETAXEL KABI 160 mg/8 ml koncentrat til infusionsvæske, opløsning docetaxel 
DOCETAXEL KABI 160 mg/8 ml concentrate for solution for infusion docetaxel
CI) **p-værdi 
(95% CI) ***p-value
Perifer sensorisk neuropati (G3/4: 0,8 %) 
Peripheral sensory neuropathy (G3/4: 0.8%)
Første episode: Reducer 5-FU-dosis med 20 % Anden episode: Reducer så docetaxel-dosis med 20 % 
Second episode: reduce docetaxel dose by 20%.
Letargi 
Arrhythmia
Et hætteglas af 4 ml koncentrat indeholder 80 mg docetaxel. 
One vial of 4 ml of concentrate contains 80 mg of docetaxel.
Tabel over bivirkninger ved behandling af brystkræft med DOCETAXEL KABI 100 mg/m² i kombination med trastuzumab: 
Tabulated list of adverse reactions in breast cancer for DOCETAXEL KABI 100 mg/m² in combination with trastuzumab
FREMSTILLINGSVEJLEDNING TIL BRUG FOR DOCETAXEL KABI 20 mg/1 ml, KONCENTRAT TIL INFUSIONSVÆSKE, OPLØSNING 
PREPARATION GUIDE FOR USE WITH DOCETAXEL KABI 20 mg/1 ml CONCENTRATE FOR SOLUTION FOR INFUSION
LÆGEMIDLETS NAVN DOCETAXEL KABI 80 mg/4 ml koncentrat til infusionsvæske, opløsning. 
NAME OF THE MEDICINAL PRODUCT DOCETAXEL KABI 80 mg/4 ml concentrate for solution for infusion
Myalgi; artralgi; smerter i ekstremiteterne; knoglesmerter; rygsmerter 
Myalgia; Arthralgia; Pain in extremity; Bone pain; Back pain
G3/4 Forhøjet bilirubin i blodet 
Weight decreased; G3/4 Blood bilirubin increased
FREMSTILLINGSVEJLEDNING TIL BRUG FOR DOCETAXEL KABI 80 mg/4 ml, KONCENTRAT TIL INFUSIONSVÆSKE, OPLØSNING 
PREPARATION GUIDE FOR USE WITH DOCETAXEL KABI 80 mg/4 ml CONCENTRATE FOR SOLUTION FOR INFUSION
Infektioner (G3/4: 5,7 
Infection (G3/4: 5.7%)
Dosisjustering under behandling: 
Dose adjustments during treatment
FREMSTILLINGSVEJLEDNING TIL BRUG FOR DOCETAXEL KABI 120 mg/6 ml, KONCENTRAT TIL INFUSIONSVÆSKE, OPLØSNING 
PREPARATION GUIDE FOR USE WITH DOCETAXEL KABI 120 mg/6 ml CONCENTRATE FOR SOLUTION FOR INFUSION
10 ml klar, farveløs Type-I hætteglas, lukket med flurotec gummipropper og en gul flip-off aluminium kapsel, indeholdende 8 ml koncentrat. 
10 ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a yellow flip-off aluminium over seal containing 8 ml of concentrate.
DOCETAXEL KABI 80 mg/4 ml koncentrat til infusionsvæske, opløsning docetaxel 
DOCETAXEL KABI 80 mg/4 ml concentrate for solution for infusion docetaxel
Almindelige bivirkninger bindevæv 
Musculoskeletal and connective bone disorders
6 ml klar, farveløs Type-I hætteglas, lukket med flurotec gummipropper og en grøn flip-off aluminium kapsel, indeholdende 1 ml koncentrat. 
6 ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a green flip-off aluminium over seal containing 1 ml of concentrate.
Tabel over bivirkninger ved behandling af brystkræft med DOCETAXEL KABI 75 mg/m² i kombination med doxorubicin: 
Tabulated list of adverse reactions in breast cancer for DOCETAXEL KABI 75 mg/m² in combination with doxorubicin
Perifer sensorisk neuropati (G3: 4,1 %); Perifer motorisk neuropati (G3/4: 4 %) Dysgeusi (alvorlig: 
Peripheral sensory neuropathy (G3: 3.7%); Peripheral motor neuropathy (G3/4: 2%)
DOCETAXEL KABI 20 mg/1 ml koncentrat til infusionsvæske, opløsning docetaxel 
DOCETAXEL KABI 20 mg/1 ml concentrate for solution for infusion docetaxel
LÆGEMIDLETS NAVN DOCETAXEL KABI 120 mg/6 ml koncentrat til infusionsvæske, opløsning. 
NAME OF THE MEDICINAL PRODUCT DOCETAXEL KABI 120 mg/6 ml concentrate for solution for infusion
Lægemidlet indeholder 50 vol % ethanol vandfri (alkohol), dvs. op til 1,58 g (2 ml) ethanol vandfri per hætteglas svarende til 40 ml øl eller 17 ml vin. 
This medicinal product contains 50 vol % ethanol anhydrous (alcohol), i.e. up to 1.58 g ethanol anhydrous per vial, equivalent to 40 ml of beer or 17 ml wine.
LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E) DOCETAXEL KABI 180 mg/9 ml koncentrat til infusionsvæske, opløsning docetaxel i.v. 
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION DOCETAXEL KABI 180 mg/9 ml concentrate for solution for infusion docetaxel
Dysgeusi (G3/4: < 1 %); 
Rash erythematous (G3/4: < 1%);
Luftveje, thorax og mediastinum Pharyngolaryngeale smerter (G3/4: 2 %) 
Pharyngolaryngeal pain (G3/4: 2%)
186 patienter blev randomiseret til at få docetaxel (100 mg/m2) med eller uden trastuzumab. 
One hundred eighty six patients were randomised to receive docetaxel (100 mg/m2) with or without trastuzumab; 60% of patients received prior anthracycline-based adjuvant chemotherapy.
Kvalme (G3/4: 13,9 %); Stomatitis (G3/4:20,7 
Nausea (G3/4: 5%); Stomatitis (G3/4: 7.8%);
6 ml klar, farveløs Type-I hætteglas, lukket med flurotec gummipropper og en rød flip-off aluminium kapsel, indeholdende 6 ml koncentrat. 
6 ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a red flip-off aluminium over seal containing 6 ml of concentrate.
Hudreaktioner (G3/4:0,2 %) 
Skin reaction (G3/4: 0.2%)
Konstipation 
Constipation
Ødemer (G3/4: 1,2%) 
Fever (G3/4: 1.2%)
Eksfoliativt udslæt 
Hepatic impairment
LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E) DOCETAXEL KABI 160 mg/8 ml koncentrat til infusionsvæske, opløsning docetaxel i.v. 
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION DOCETAXEL KABI 160 mg/8 ml concentrate for solution for infusion docetaxel
Tabel over bivirkninger ved behandling af gastrisk adenokarcinom med DOCETAXEL KABI 75 mg/m² i kombination med cisplatin og 5-fluoruracil: 
Tabulated list of adverse reactions in gastric adenocarcinoma center for DOCETAXEL KABI 75 mg/m² in combination with cisplatin and 5-fluorouracil
Sikkerheden og effekten af docetaxel i den indledende behandling af patienter med lokalt fremskredent pladecellecarcinom i hoved og hals (SCCHN) blev evalueret i et randomiseret, multicenter, open-label fase III studie (TAX 324). 
• Induction chemotherapy followed by chemoradiotherapy (TAX324) The safety and efficacy of docetaxel in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a randomised, multi centre open-label, phase III, study (TAX324).
6 ml klar, farveløs Type-I hætteglas, lukket med flurotec gummipropper og en blå flip-off aluminium kapsel, indeholdende 4 ml koncentrat. 
6 ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a blue flip-off aluminium over seal containing 4 ml of concentrate.